Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02358681 · ClinicalTrials.gov registry record · Phase 3
Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children
A Phase 3 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
NCT02358681 is a Phase 3 study that has completed, run by Columbia University. The registered enrollment target is 59 participants.
The verdict
NCT02358681, a Phase 3 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
Study Summary
Ketorolac is an evidence-based, first-line acute migraine therapy that is commonly used in the pediatric population; however, it is typically administered by the intravenous (IV) or intramuscular (IM) routes, both of which require a painful and distressing needle stick to administer. The intranasal (IN) route is a painless and effective way of administering analgesics, including ketorolac: IN ketorolac has been shown to be an effective analgesic in adults for painful conditions, including acute migraine headaches. However, IN ketorolac has been understudied in children, and it is not known how effective it is compared to IV ketorolac, which is currently the most common way of administering ketorolac to children. If IN ketorolac is shown to be no less effective than IV ketorolac, IN ketorolac may be a viable and painless alternative to effectively treat acute migraine headaches in children. Therefore, our primary aim is to demonstrate that IN ketorolac is non-inferior to IV ketorolac for reducing pain in children with acute migraine headaches.
Interventions
- DRUG Ketorolac, intranasal
- DRUG Ketorolac, intravenous
- DRUG Placebo, intravenous
- DRUG Placebo, intranasal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2015-06-16 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02358681
The ClinicalTrials.gov registry entry for NCT02358681 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ketorolac, intranasal is the first listed.
NCT02358681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02358681 about?
NCT02358681 is a clinical study titled "Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children". Ketorolac is an evidence-based, first-line acute migraine therapy that is commonly used in the pediatric population; however, it is typically administered by the intravenous (IV) or intramuscular (IM) routes, both of which require a painful and distressing needle stick to administer. The intranasal...
What is the current status of trial NCT02358681?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2015-06-16. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT02358681?
The interventions under investigation include: Ketorolac, intranasal (DRUG), Ketorolac, intravenous (DRUG), Placebo, intravenous (DRUG), Placebo, intranasal (DRUG).
Who is sponsoring clinical trial NCT02358681?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.